Fresenius Medical Care Takes 110M Euro Charge on China Strategy Shift

Key Facts

1Fresenius Medical Care updated its China strategy with a focus on advanced dialysis technology.

2The company incurred a non-cash charge of 110 million euros due to the restructuring of its product portfolio in the Chinese market.

Fresenius Medical Care updated its China strategy with a focus on advanced dialysis technology. Benzinga reported that the company incurred a non-cash charge of 110 million euros due to the restructuring of its product portfolio in the Chinese market. The shift aims to optimize operations to align with evolving market dynamics.

The portfolio optimization prioritizes high-end medical equipment to drive long-term efficiency. Regarding the broader economic context in China, the 1-year Loan Prime Rate was recorded at 3% on September 20, 2026, while the 5-year rate stood at 3.5% on the same date.